Vivos Inc. Pilot Clinic Completes First IsoPet® Therapy
July 11, 2019 07:00 ET | Source: Vivos Inc.
Richland WA, July 11, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCPINK: RDGLD), Dr. Michelle Meyers, IsoPet® certified veterinarian practicing at Vista Veterinary Hospital, treated their first patient, a cat named Drake. The patient has already been released since this is same-day therapy.
Drake’s spindle cell sarcoma had been treated previously with external beam therapy but the tumor reoccurred. In this therapy Dr. Meyer focused on treating the margins around the tumor to reduce the chance of re-occurrence. The pet’s owner is a veterinarian from Sitka Alaska. He had researched the options and decided that IsoPet was his best choice to extend the life of his cat.
Dr. Mike Korenko stated “This therapy is the culmination of more than two years of dedicated work to bring Isopet® to market. We will be screening patients for future therapies. The current pricing for Isopet® is competitive with external beam therapy, with the advantage that Y-90 IsoPet® can deliver much higher doses in a single treatment and is precision targeted with insignificant collateral damage to healthy tissue. Over time and as patient volumes increases, we will continue to work to reduce production costs to significantly expand our customer base.” Isopet® provides certified veterinarians with an on-demand next generation cancer therapy alternative without the significant capital expenditure associated with traditional beam therapy. Pet owners who choose Isopet® will know that this important expenditure provides their pet with a powerful new treatment that can dramatically enhance quality of life without the need for the repeated treatment typically required by traditional beam therapy.”
We have created a portal on our web page for interested pet owners to submit their Expression of Interest Application. These will be reviewed by Vista Veterinary Hospital. Any direct callers to Vista will be sent this same application and they will be included in this same screening process.
"Evaluate the ingredients before drinking the Kool-Aid."
